Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom
High confidence: full text extraction produced 1844 characters.
Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy
● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.
Why it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. "This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes," said Elvinix chief executive Daniil Koshelev.
Read more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026